News

    Published March 30, 2026

    Cellevate secures SEK 21.3 Million financing to advance commercialization

    LUND, Sweden – March 30, 2026 – Cellevate AB today announced the successful closing of a new financing round in February 2026, raising SEK 21.3 million from a combination of existing shareholders and new investors, including Almi Invest. The strong participation from both current and new investors reflects continued confidence in Cellevate’s strategy, execution capabilities,…

    Published March 23, 2026

    Cellevate announces leadership change

    LUND, Sweden – March 23, 2026 – Cellevate today announces leadership change as CEO Laura Chirica moves on to new opportunities. The Board of Directors has appointed Karsten Fjärstedt as Interim CEO, effective immediately. The Board has initiated a search process for a permanent CEO and will announce a successor in due course. The Board…

    Published March 10, 2026

    Cellevate AB and InVitria Inc. enter strategic collaboration to advance upstream bioprocessing solutions for viral vaccine production

    LUND, Sweden – March 10, 2026 – Cellevate AB today announces a strategic collaboration agreement with InVitria, Inc., a U.S.-based leader in chemically defined, animal-component-free cell culture media and recombinant protein solutions. The collaboration will execute a joint development program integrating InVitria’s high-performance media with Cellevate’s Cellevat3d® nanofiber microcarrier platform. The program includes microcarrier screening,…

    Published February 18, 2026

    Cellevate selected to enter negotiations with EIC Fund for potential follow-on equity investment to support the company’s next growth phase in vaccine manufacturing

    LUND, Sweden – February 18, 2026 – Cellevate today announces that the company has been selected to enter negotiations with the European Innovation Council (EIC) Fund regarding a potential follow-on equity investment, to be syndicated with new investors in a financing round planned for the second half of 2026. The financing will support Cellevate’s next…

    Published December 16, 2025

    Cellevate caps strong 2025 by achieving ISO 9001:2015 certification and implementing GMP production processes in new cleanroom

    LUND, Sweden – December 16, 2025 – Cellevate announces that it has achieved ISO 9001:2015 certification combined with GMP processes in cleanroom, marking a major milestone for Cellevate to becoming an industrial bioprocessing supplier. The certification reflects Cellevate’s dedication to delivering the highest standard of quality assurance throughout all its processes, from the business plan…

    Published October 13, 2025

    Cellevate to announce major advances in yield and scalability of viral vaccine production at World Vaccine Congress Europe with global launch of Cellevat3d® VAX nanofiber microcarriers

    LUND, Sweden, October 13, 2025 – Cellevate AB today announced the upcoming global launch at the World Vaccine Congress Europe in Amsterdam, October 14–16, 2025 of Cellevat3d® VAX nanofiber microcarriers for adherent cell-based viral vaccine production. Join our launch event and company presentation on October 16 at 12:30 in the Manufacturing Technologies track, where CTO…

    Published August 19, 2025

    More than 10-fold enhanced viral vaccine production titers using the novel Cellevat3d® nanofiber microcarriers

    LUND, Sweden, August 19, 2025 – Cellevate AB publishes today results from their vaccine production validation program that is designed to evaluate and validate the performance of the cell culture products based on proprietary nanotechnology Cellevat3d®. In internal studies, the data demonstrated that Vero cells cultured on Cellevat3d® nanofiber microcarriers rapidly formed dense and uniform…

    Published April 25, 2025

    Cellevate, Fraunhofer IBMT and OLS consortium awarded EUR 1 million Eurostar grant for large scale production of induced pluripotent stem cells

    LUND, Sweden, April 25, 2025 – Cellevate AB, Fraunhofer IBMT (Institute for Biomedical Engineering), and the German bioreactor company OLS (Omni Life Science) have been awarded a EUR 1 million grant through the Eurostar program for large scale production of iPSCs (induced pluripotent stem cells). The project will run for three years and aims to…

    Published March 17, 2025

    Cellevate hosts Global Webinar presenting latest data and process economy savings in viral vector production with Cellevat3d® nanofiber microcarriers – April 1, 2025 at 17:00 CET

    LUND, Sweden, March 17, 2025 – Following the interest since the launch of the world’s first nanofiber-based cell culture systems at the end of 2024, Cellevate is pleased to announce a 2nd webinar on the productivity increases and resulting cost reductions based on a process economy model for large-scale gene therapy production. Held in collaboration…

    Published March 12, 2025

    Cellevate strengthens management team with the appointment of Dr. Christel Fenge as Chief Technology Officer

    Lund, Sweden, 12 March 2025 – Cellevate AB, an innovative biotech company developing next-generation cell culture solutions to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as Chief Technology Officer (CTO) and member of the management team. Dr. Fenge, who has served as a Strategic Advisor to Cellevate since June 2024,…